On a clinical trial level, in a subgroup analysis of a Phase III trial of temsirolimus, an mTOR inhibitor, in poor-prognosis RCC of all subtypes, patients of non-clear cell histology benefited as much as patients with clear cell histology, if not more [21]. Here, MTOR is linked to renal cell carcinoma.